AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03856294 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo, 2,5g dissolved in 200 mL lukewarm water, three times daily, 30min before meal intake
Study NCT02637947 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: catheter ablation using magnetic navigation
Description: elimination of cardiac arrhythmias through heating and destroying heart tissue with faulty electrical pathways through the use of Stereotaxis's Niobe ES System with the NaviStar RMT ThermoCool catheter or other magnetically compatible catheters.
Study NCT02637947 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: catheter ablation using manual navigation
Description: elimination of cardiac arrhythmias through heating and destroying heart tissue with faulty electrical pathways through the use of the NaviStar ThermoCool catheter or other manually navigated catheters.
Study NCT01292499 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: 10 sessions (50 min)
Study NCT01292499 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: 7 sessions + 7 phone calls
Study NCT01292499 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation and psychotherapy
Description: Psychoeducation + psychotherapy
Study NCT02066298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat 5mcg QD
Description: Tiotropium is a LMA
Study NCT02066298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02454426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: open label treatment
Study NCT02106793 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Identical placebo solution
Description: Identical placebo solution
Study NCT01417208 — intervention group
Intervention type: DEVICE
Intervention: SNaP® Wound Care System
Description: Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
Study NCT04542993 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc Picolinate
Description: Zinc Picolinate (50 mg PO TID x 5 days)
Study NCT04542993 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol
Description: Resveratrol 2 grams po BID x 5 days
Study NCT04542993 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Zinc Picolinate Placebo
Description: Zinc Picolinate Matched Placebo PO TID x 5 days
Study NCT04542993 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Resveratrol Placebo
Description: Resveratrol Matched Placebo PO BID x 5 days
Study NCT04593992 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HTEMS
Description: high-tone external muscle stimulation
Study NCT04593992 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo stimulation
Study NCT00297453 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based smoking treatment
Description: All participants have access to an Internet-based self-help intervention that includes social support through message boards. All participants have access to 10 weeks of nicotine replacement treatment.
Study NCT00297453 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Counseling
Description: Six individual counseling sessions are provided over a 12 week treatment period. Participants also have access to a 10-week nicotine replacement treatment.
Study NCT00297453 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: self-help
Description: Participants receive a self-help manual and have access to a 10 nicotine replacement treatment.
Study NCT01169857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: Velcade at 1.3 mg/m2, on days 1, 4, 8 and 11 (=1 cycle). The study will involve 3 cycles of Velcade therapy.
Study NCT03299140 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Family Focused Therapy
Study NCT03855215 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ACTIM CRP Rapid Test (Medix, Biochemica)
Description: The implementation of CRP point of care tests will be conducted at commune health centres (CHCs), the primary access point for public health services in Vietnam. In the intervention CHCs, healthcare workers will be trained on the use and interpretation of CRP testing in ARI. healthcare workers can decide to follow the test results or not.
Study NCT05361473 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The NeoHilda Point of care method
Description: This is a procedure that measures Lactate dehydrogenase in a fast and reliable way from only 10 microliter of blood. Using a small point of care card and a Smartphone for analysis.
Study NCT05361473 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Traditional evaluation
Description: Traditional way of evaluation
Study NCT02398097 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Agripal
Description: 2011/2012 influenza season standard dose trivalent subunit inactivated intramuscular vaccine, single dose
Study NCT02398097 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IDflu9μg
Description: 2011/2012 influenza season reduced-content intradermal split vaccine, single dose
Study NCT02398097 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IDflu15μg
Description: 2011/2012 influenza season standard-content intradermal split vaccine, single dose
Study NCT03574792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Given PO
Study NCT03574792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Given PO
Study NCT03574792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Given PO
Study NCT03574792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Given PO
Study NCT03574792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Given PO
Study NCT03574792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Given PO
Study NCT03574792 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03574792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03574792 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03574792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03574792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Given PO
Study NCT03574792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine Hydrochloride Extended Release
Description: Given PO
Study NCT01265953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SFN-rich broccoli sprout extract capsules
Description: Four weeks SFN-rich broccoli sprout extract (BSE) capsules: 200µmol of SFN, 2 capsules (1 capsule B.I.D.) daily
Study NCT01265953 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Gelatin capsule containing microcrystalline cellulose.
Description: Four weeks placebo capsules: 2 capsules (1 capsule B.I.D.) daily
Study NCT03423537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCG
Description: the addition of hCG (Pregnyl®, MSD Greece) will begin with the administration of gonadotrophin at a dose of 100 IU per day, administered subcutaneously, and will continue until the administration of hCG for follicular maturation.
Study NCT03423537 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100IU per day containing N/S 0.9% will be injected
Study NCT04560322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet, taken by mouth
Study NCT04560322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Intravenous infusion
Study NCT04560322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Capsule, taken by mouth
Study NCT04169906 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo once daily for 7 consective days
Study NCT04169906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo once daily for 7 consective days
Study NCT04169906 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TS-142, 10 mg
Description: Participants will receive 10 mg of TS-142 once daily for 7 consective days
Study NCT04169906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142, 10 mg
Description: Participants will receive 10 mg of TS-142 once daily for 7 consective days
Study NCT04169906 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TS-142, 20 mg
Description: Participants will receive 20 mg of TS-142 once daily for 7 consective days
Study NCT04169906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142, 20 mg
Description: Participants will receive 20 mg of TS-142 once daily for 7 consective days
Study NCT04169906 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TS-142, 30 mg
Description: Participants will receive 30 mg of TS-142 once daily for 7 consective days
Study NCT04169906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142, 30 mg
Description: Participants will receive 30 mg of TS-142 once daily for 7 consective days
Study NCT04056598 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Study of humoral immunity
Description: Analysis: Surface antigen ELISA, recognition of living P. acnes bacteria via FACS, 16SRNA study of microbiome, SLST typing of P. acnes bacteria
Study NCT01825551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granulocyte Colony Stimulating Factor
Study NCT01825551 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00664612 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AirTraq
Description: Laryngoscopy with AirTraq
Study NCT01979926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of Broussonetia spp and Lonicera spp
Description: 600 mg/ day or 1200 mg/ day for 7 days
Study NCT04117711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-007
Description: AT-007 will be administered once daily before breakfast. Up to 4 different dose cohorts in part A; up to 4 dose cohorts in part B, up to 2 dose cohorts for part C, and up to 3 dose cohorts for part D will be enrolled in the study. The starting dose in Part A will be 0.5 mg/kg as a single dose. Subsequent doses in Part A and all doses in Parts B, C, and D will be based on the results of previous cohorts and/or previous parts of the study. Part B will start after all subjects in Part A have completed the study. Cohort C1 will be conducted simultaneously with Cohort B3 and using the same dose as Cohort B2. The dose for Cohort D1 will not be higher than the dose for Cohort B2. The second and third cohorts in Part D (D2 and D3) will not start until after all subjects in Cohorts B3 and B4, respectively, have completed the study and the dose levels will not be higher than those for Cohorts B3 and B4, respectively.
Study NCT04117711 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered once in the morning before breakfast
Study NCT03455153 — intervention group
Intervention type: OTHER
Intervention: Physical activity monitoring
Description: COPD patients will wear an accelerometer and complete questionnaires related to daily physical activity levels for 7 days before returning for a clinic visit.
Study NCT01979926 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Combination of Broussonetia spp and Lonicera spp
Description: 600 mg/ day or 1200 mg/ day for 7 days
Study NCT04029727 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Combination of Plant Extracts (BSL_EP025)
Description: Each participant will consume 2 capsules daily at lunch for 8 weeks.
Study NCT04029727 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant will consume 2 capsules daily at lunch for 8 weeks.
Study NCT03192566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tylenol
Description: Dosing of Tylenol for post operative pain control
Study NCT01881217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1179470
Description: BAY1179470 will be administered as a 1-hour intravenous infusion.
Study NCT01016730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV
Study NCT04074798 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: assessment of hyperventilation, postural control and psychological behavior
Description: assessment of hyperventilation, postural control and psychological behavior
Study NCT04074798 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: assessment of hyperventilation, postural control and psychological behavior
Description: assessment of hyperventilation, postural control and psychological behavior
Study NCT04731909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab 240mg,ivgtt,d1,q3w.
Study NCT04731909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib 12 mg/d,d1-14,q3w,4-6 cycles in total. In maintenance treatment period, Anlotinib 12 mg/d,d1,Oral for 2 weeks and stop for 1 week.
Study NCT04731909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m2,d1,q3w,4-6 cycles in total.
Study NCT04731909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC=5,d1,q3w,4-6 cycles in total.
Study NCT04504097 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: m-Health
Description: Participants receive a weekly bidirectional text message (SMS) asking how they are doing. They are requested to reply fine, or not fine, in which case they will be contacted with support by a peer navigator. If they do not reply to the message within the specified timeframe a peer navigator will follow up with them.
Study NCT04504097 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: HIV self-testing
Description: Participants will receive HIVST kits so that they can perform their HIV testing.
Study NCT03756558 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cross-Seal System
Description: Use of the Cross-Seal system to close the femoral arteriotomy
Study NCT04504097 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HIV self-testing
Description: Participants will receive HIVST kits so that they can perform their HIV testing.
Study NCT02575599 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guided self-determination programme (GSD)
Description: The GSD intervention consist of four e-consultations with structured reflection sheets. Reflection sheets are intended to increase patients' ability to express their views and prepare them for active participation in the care process. Through the web-based platform, the subsequent four e-consultations will allow for communication between patients and nurses. The platform allows the participants to fill in the reflection sheets using their own words and drawings to express their own experiences with self-management as well as to formulate behavioral goals and plans to achieve their goals. It also permits feedback from the nurses on these reflections sheets via secure emails. Each person will be able to access the web-based program from his or her own computers or other electronic devices.
Study NCT02965560 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: plasma suPAR, PGE2 measurement. Other biomarkers were just recorded from clinical laboratory.
Study NCT01976663 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUVEDERM VOLIFT® XC
Description: Up to 4 mLs JUVEDERM VOLIFT® XC injected intradermally in one NLF (total; including initial and touch-up treatments) and up to 4 mLs JUVEDERM VOLIFT XC is allowed for repeat treatment. For asymmetric correction, only the more severe NLF is eligible for asymmetric correction.
Study NCT01976663 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Up to 4 mLs Control injected intradermally in opposite NLF (total; including initial and touch-up treatments). Up to 4 mLs JUVEDERM VOLIFT XC is allowed for asymmetry correction and up to 4 mLs JUVEDERM VOLIFT XC is allowed for repeat treatment. Only the more severe NLF is eligible for asymmetric correction.
Study NCT01810393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be administered at a dose of 6 milligrams per kilogram (mg/kg) IV or 600 milligrams per 5 milliliter (mg/5mL) SC in 21-day cycles as per schedule described in respective arm.
Study NCT03199846 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study NCT00445458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HKI-272
Study NCT00445458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT04097132 — intervention group
Intervention type: DEVICE
Intervention: echocardiography
Description: echocardiography for left atrial diameter, size ,Ejection Fraction Holter for detection of paroxusmal AF
Study NCT03794089 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief anxiety intervention
Description: Modular anxiety intervention, tailored for Veterans, with emphasis on adaptive coping skills
Study NCT03794089 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual PC-MHI care
Description: Anxiety treatment with mental health provider in local primary care clinic
Study NCT03888144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: 5 mg of oxycodone taken by mouth every 6 hours for 5 days
Study NCT03888144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: 10 mg of ketorolac taken by mouth every 6 hours for 5 days
Study NCT01045447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Treat-to-target dose titration scheme, injected subcutaneously (under the skin) once daily with main meal. Dose was individually adjusted.
Study NCT03464786 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lando® absorbable collagen membrane
Description: Subjects who are fit for the study will be randomized to either intervention arms.
Study NCT03464786 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Geistlich Bio-Gide resorbable bilayer membrane
Description: Subjects who are fit for the study will be randomized to either intervention arms.
Study NCT02629380 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hyaluronic acid
Description: A single injection of 3 ml hyaluronic acid to be performed under arthroscopic view at the end of meniscectomy
Study NCT02629380 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: meniscectomy alone
Description: The patients randomized in this group will receive arthroscopic meniscectomy alone
Study NCT00535301 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: grafted anterior prolapse repair
Description: anterior vaginal prolapse repair with graft
Study NCT01016730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01016730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01045447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Treat-to-target dose titration scheme, injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
Study NCT01438411 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cholic Acid
Description: 10-15 mg/kg body weight/day supplied in 50 or 250 mg Cholic Acid Capsules
Study NCT00004867 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT00004867 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Study NCT00004867 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radionuclide imaging
Study NCT00004867 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Study NCT00004867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Study NCT00004867 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study NCT02092948 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [124I] PSCA-Minibody PET/CT imaging of the whole body
Description: Whole body Imaging
Study NCT02673658 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motor + problem solving
Description: Developmental motor tasks incorporating cognitive concepts such as object permanence